Germana Lissidini, Luca Nicosia, Manuela Sargenti, Maria Cristina Cucchi, Alessandra Fabi, Giuseppe Falco, Marco Gardani, Greta Grilz, Ilaria Maugeri, Roberto Murgo, Alessandro Neri, Francesca Pellini, Cristiana Sensi, Serena Scomersi, Mario Taffurelli, Vincenzo Bagnardi, Chiara Oriecuia, Eleonora Pagan, Claudia Sangalli, Massimo Dessena, Paolo Veronesi, Viviana Galimberti
{"title":"男性乳腺癌：一项多中心研究，为正确治疗提供指导。","authors":"Germana Lissidini, Luca Nicosia, Manuela Sargenti, Maria Cristina Cucchi, Alessandra Fabi, Giuseppe Falco, Marco Gardani, Greta Grilz, Ilaria Maugeri, Roberto Murgo, Alessandro Neri, Francesca Pellini, Cristiana Sensi, Serena Scomersi, Mario Taffurelli, Vincenzo Bagnardi, Chiara Oriecuia, Eleonora Pagan, Claudia Sangalli, Massimo Dessena, Paolo Veronesi, Viviana Galimberti","doi":"10.1007/s10549-024-07380-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To offer an extensive retrospective experience on the management of male breast cancer.</p><p><strong>Methods: </strong>A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.</p><p><strong>Results: </strong>In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).</p><p><strong>Conclusion: </strong>Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Male breast cancer: a multicenter study to provide a guide for proper management.\",\"authors\":\"Germana Lissidini, Luca Nicosia, Manuela Sargenti, Maria Cristina Cucchi, Alessandra Fabi, Giuseppe Falco, Marco Gardani, Greta Grilz, Ilaria Maugeri, Roberto Murgo, Alessandro Neri, Francesca Pellini, Cristiana Sensi, Serena Scomersi, Mario Taffurelli, Vincenzo Bagnardi, Chiara Oriecuia, Eleonora Pagan, Claudia Sangalli, Massimo Dessena, Paolo Veronesi, Viviana Galimberti\",\"doi\":\"10.1007/s10549-024-07380-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>To offer an extensive retrospective experience on the management of male breast cancer.</p><p><strong>Methods: </strong>A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.</p><p><strong>Results: </strong>In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).</p><p><strong>Conclusion: </strong>Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.</p>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10549-024-07380-0\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07380-0","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
摘要
简介：目的提供男性乳腺癌治疗的广泛回顾性经验：开展了一项多中心回顾性观察队列研究，包括1975年1月至2019年12月期间在意大利12个乳腺科确诊为乳腺癌（浸润性或原位）的男性患者。年满 18 周岁的患者均接受了资格评估。排除标准为确诊时为转移性癌症、曾患癌症、接受过新辅助治疗、（新）辅助治疗数据不完整和/或随访数据不完整。研究人员收集了放射学检查、人口统计学特征、风险因素、组织学特征、受体状态、治疗和随访数据：在一系列经过资格评估的 671 名男性乳腺癌患者中，有 403 名（28 名原位癌患者和 375 名浸润性肿瘤患者）被纳入研究。所有患者均接受了手术治疗。手术时的中位年龄为 63.8 岁（IQR 56.1-72.1）。68%的患者接受了超声波检查，55.1%的患者接受了乳房X光检查。大多数患者ER和PR阳性（63.8%），HER2阴性（80.4%），Ki67值高（≥20%）（61.3%），管腔B亚型（51.1%）。浸润性乳腺癌患者的10年总生存率为73.6%（95% CI 67.0-79.1），原位乳腺癌患者的10年总生存率为90%（95% CI 65.6-97.4）。在浸润性乳腺癌患者中，在单变量分析中，G3肿瘤（与G1相比）、pT2/3/4（与pT1相比）、pN2/3（与pN0相比）、Ki67≥20%的管腔B亚型（与管腔A相比）与较高的死亡风险显著相关。在多变量分析中，pT2/3/4（vs.pT1）仍与较高的死亡风险显著相关（HR 3.14，95% CI 1.83-5.39），HER2阳性或三阴性亚型（vs.管腔A）也与较高的死亡风险显著相关（HR 4.76，95% CI 1.26-18.1）：男性乳腺癌是一种罕见疾病，有必要对其有更深入的了解，以便采取更有效的诊断和治疗方法。
Male breast cancer: a multicenter study to provide a guide for proper management.
Introduction: To offer an extensive retrospective experience on the management of male breast cancer.
Methods: A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.
Results: In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).
Conclusion: Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
